Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Liraglutide (Saxenda®) has been rejected for use as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of:

  • ≥30kg/m2 (obese)
  • ≥27kg/m2 and <30kg/m2 (overweight) with at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea

The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2017' on Email Share 'SMC Update - May 2017' on Delicious Share 'SMC Update - May 2017' on Digg Share 'SMC Update - May 2017' on Facebook Share 'SMC Update - May 2017' on reddit Share 'SMC Update - May 2017' on StumbleUpon Share 'SMC Update - May 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer